Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $13.80

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $13.80.

A number of equities research analysts have weighed in on the stock. Barclays began coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 target price for the company. Truist Financial set a $15.00 price objective on Amneal Pharmaceuticals in a report on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and issued a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st.

Amneal Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ AMRX opened at $14.82 on Friday. The firm’s 50-day moving average price is $13.28 and its 200-day moving average price is $11.32. Amneal Pharmaceuticals has a 52-week low of $6.68 and a 52-week high of $15.00. The company has a market cap of $4.66 billion, a PE ratio of 741.37 and a beta of 1.36.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Federated Hermes Inc. raised its holdings in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Comerica Bank increased its position in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in shares of Amneal Pharmaceuticals in the third quarter worth about $31,000. Spire Wealth Management lifted its position in shares of Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after buying an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC grew its stake in shares of Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares during the period. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.